Here are the 10-K annual reports from Cryo-Cell International Inc. (CCEL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCEL filings page.
Cryo-Cell International, Inc. provides cord blood and cord tissue processing and storage, manufactures the PrepaCyte CB processing system, and operates both private and public cord blood banking, including units listed through the National Marrow Donor Program.
The company highlights its cGMP/cGTP-compliant facilities, AABB and FACT accreditations, over 250,000 specimens stored with global affiliates, and a new Durham, North Carolina facility that also supports the ExtraVault third‑party cold storage service for biopharma customers.
A central theme is the now-contested Duke License Agreement. Cryo-Cell alleges Duke fraudulently induced and then breached the agreement, has filed an arbitration demand claiming damages it believes exceed $100 million, and has recorded a full impairment of the related asset. Duke has issued a notice of termination effective May 17, 2025 and asserted counterclaims for breach and indemnity, with a final arbitration hearing scheduled for April 2026.
Until this dispute is resolved, expansion into infusion clinics and biopharmaceutical manufacturing, the opening of the Cryo-Cell Institute for Cellular Therapies, and the proposed spin-off of its Celle Corp. subsidiary are all on hold, and the company cautions that the arbitration outcome could materially affect its business and financial position.